Skip to main content

Table 5 Time to initially attained target Hb level (10–12 g/dL) and proportion of patients attained target Hb level (10–12 g/dL) at EOC and EOM

From: Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial

Parameter

ITT Population (N = 126)

PP Population (N = 93)

Darbepoetin alfa (n = 63)

Erythropoietin alfa (n = 63)

Darbepoetin alfa (n = 47)

Erythropoietin alfa (n = 46)

Number of weeks to initially attain target Hb

 Median (95%CI)

9.00 (7.00–11.00)

7.00 (4.00–9.00)

9.00 (7.00–10.00)

7.00 (4.00–8.00)

No. of Patients initially attained target Hb level

 N (%)

44 (78.57)

43 (82.69)

40 (85.10)

41 (89.13)

 Hazard Ratio (95%CI)

0.807 (0.53–1.23)

0.778 (0.50–1.21)

P Value

0.3212

0.2608

No. of patients attained target Hb level at EOC

 N (%)

33 (52.38)

31 (49.2)

32 (68.08)

32 (69.56)

 Odd ratios (95%CI)

0.9559 (0.46–1.99)

0.9410 (0.39–2.30)

P value

0.9038

0.8938

No. of patients maintained target Hb level at EOM

  (%)

24 (38.10)

36 (57.14)

15 (34.09)

23 (57.50)

 Odd ratios (95%CI)

0.5748 (0.26–1.25)

0.4567 (0.17–1.22)

P Value

0.1621

0.1180

  1. EOC End of correction, EOM End of maintenance, ITT Intent to treat, PP Per protocol, Hb Hemoglobin